28222462|t|Decreased Frequencies of Peripheral Blood CD4+CD25+CD127-Foxp3+ in Patients with Graves' Disease and Graves' Orbitopathy: Enhancing Effect of Insulin Growth Factor-1 on Treg Cells
28222462|a|Graves' orbitopathy (GO) is characterized by orbital T cell infiltration. We evaluated the regulatory T (Treg) cell fractions induced with IGF-1 in Graves' disease (GD) with and without GO. Peripheral blood mononuclear cells (PBMCs) were obtained from 13 patients with GD without eye manifestations; 10 patients with active GO; and 12 patients with nodular goiter (NG). All the patients from GD, GO, and NG were subclinical hyperthyroid. We analyzed the expression of Treg cell markers (CD4, CD25, CD127(-), Foxp3) on T cells and their ability to respond to IGF-1 stimulation. In patients with GD without GO, we found lowered percentages of CD4(+) Foxp3(+) cells, as compared to nodular goiter 1.77 vs. 5.42% (p=0.0276). Similarly, significantly reduced frequencies of CD4(+)CD25(+)CD127(-)Foxp3(+) and CD4(+)CD25(+)CD127(-) cells were observed in GD patients as compared to nodular goiter patients with hyperthyreosis, (0.7 vs. 1.48%) (p=0.0071) and (14.5 vs. 37.2%) (p=0.0051), respectively. In GO with active GO, only the percentage of CD4(+)CD25(+)CD127(-) cells was found to be decreased versus nodular goiter (9.35 vs. 37.2) (p=0.0275). Stimulation of PBMC derived from GO patients with IGF-1 resulted in significant increase of frequency of both CD4(+) Foxp3(+) and CD4(+)CD25(+)CD127(-) Foxp3 cells. Decreased frequencies of peripheral blood CD4(+)CD25(+)CD127(-)Foxp3(+) in patients with GD and GO could be an useful marker of autoimmune process and perhaps a possible target for future therapies. This is the first study demonstrating Treg - enhancing effects of IGF-1. Thus IGF-1 can be accounted for modulating Treg cell -related action in GO.
28222462	0	21	Decreased Frequencies	T080	C1561548
28222462	25	41	Peripheral Blood	T031	C0229664
28222462	42	63	CD4+CD25+CD127-Foxp3+	T025	C0039198
28222462	67	75	Patients	T101	C0030705
28222462	81	96	Graves' Disease	T047	C0018213
28222462	101	120	Graves' Orbitopathy	T047	C0339143
28222462	122	138	Enhancing Effect	T080	C1280500
28222462	142	165	Insulin Growth Factor-1	T116,T123	C0021665
28222462	169	179	Treg Cells	T025	C0039198
28222462	180	199	Graves' orbitopathy	T047	C0339143
28222462	201	203	GO	T047	C0339143
28222462	208	221	characterized	T052	C1880022
28222462	225	239	orbital T cell	T025	C0039194
28222462	240	252	infiltration	T046	C0332448
28222462	257	266	evaluated	T058	C0220825
28222462	271	295	regulatory T (Treg) cell	T025	C0039198
28222462	296	305	fractions	T081	C1264633
28222462	306	313	induced	T169	C0205263
28222462	319	324	IGF-1	T116,T123	C0021665
28222462	328	343	Graves' disease	T047	C0018213
28222462	345	347	GD	T047	C0018213
28222462	366	368	GO	T047	C0339143
28222462	370	404	Peripheral blood mononuclear cells	T025	C1321301
28222462	406	411	PBMCs	T025	C1321301
28222462	435	443	patients	T101	C0030705
28222462	449	451	GD	T047	C0018213
28222462	460	478	eye manifestations	T184	C0015411
28222462	483	491	patients	T101	C0030705
28222462	497	503	active	T169	C0205177
28222462	504	506	GO	T047	C0339143
28222462	515	523	patients	T101	C0030705
28222462	529	543	nodular goiter	T047	C0018023
28222462	545	547	NG	T047	C0018023
28222462	558	566	patients	T101	C0030705
28222462	572	574	GD	T047	C0018213
28222462	576	578	GO	T047	C0339143
28222462	584	586	NG	T047	C0018023
28222462	592	616	subclinical hyperthyroid	UnknownType	C0745142
28222462	621	629	analyzed	T062	C0936012
28222462	634	665	expression of Treg cell markers	T059	C0600223
28222462	667	670	CD4	T116,T129,T192	C0003323
28222462	672	676	CD25	T116,T129,T192	C0007507
28222462	678	686	CD127(-)	T116,T129,T192	C0083032
28222462	688	693	Foxp3	T116,T123	C4282118
28222462	698	705	T cells	T025	C0039194
28222462	727	737	respond to	T170	C1553423
28222462	738	743	IGF-1	T116,T123	C0021665
28222462	744	755	stimulation	T070	C1948023
28222462	760	768	patients	T101	C0030705
28222462	774	776	GD	T047	C0018213
28222462	785	787	GO	T047	C0339143
28222462	798	817	lowered percentages	T081	C0439165
28222462	821	842	CD4(+) Foxp3(+) cells	T025	C0039198
28222462	859	873	nodular goiter	T047	C0018023
28222462	912	945	significantly reduced frequencies	T080	C1561548
28222462	949	978	CD4(+)CD25(+)CD127(-)Foxp3(+)	T025	C0039198
28222462	983	1010	CD4(+)CD25(+)CD127(-) cells	T025	C0039198
28222462	1016	1024	observed	T169	C1441672
28222462	1028	1030	GD	T047	C0018213
28222462	1031	1039	patients	T101	C0030705
28222462	1055	1069	nodular goiter	T047	C0018023
28222462	1070	1078	patients	T101	C0030705
28222462	1084	1098	hyperthyreosis	T047	C0020550
28222462	1177	1179	GO	T047	C0339143
28222462	1185	1191	active	T169	C0205177
28222462	1192	1194	GO	T047	C0339143
28222462	1205	1215	percentage	T081	C0439165
28222462	1219	1246	CD4(+)CD25(+)CD127(-) cells	T025	C0039198
28222462	1263	1272	decreased	T081	C0205216
28222462	1280	1294	nodular goiter	T047	C0018023
28222462	1323	1334	Stimulation	T070	C1948023
28222462	1338	1342	PBMC	T025	C1321301
28222462	1356	1358	GO	T047	C0339143
28222462	1359	1367	patients	T101	C0030705
28222462	1373	1378	IGF-1	T116,T123	C0021665
28222462	1391	1424	significant increase of frequency	T080	C1561548
28222462	1433	1448	CD4(+) Foxp3(+)	T025	C0039198
28222462	1453	1486	CD4(+)CD25(+)CD127(-) Foxp3 cells	T025	C0039198
28222462	1488	1509	Decreased frequencies	T080	C1561548
28222462	1513	1529	peripheral blood	T031	C0229664
28222462	1530	1559	CD4(+)CD25(+)CD127(-)Foxp3(+)	T025	C0039198
28222462	1563	1571	patients	T101	C0030705
28222462	1577	1579	GD	T047	C0018213
28222462	1584	1586	GO	T047	C0339143
28222462	1599	1612	useful marker	T201	C0005516
28222462	1616	1634	autoimmune process	T046	C0443146
28222462	1669	1685	future therapies	T169	C0039798
28222462	1705	1710	study	T062	C2603343
28222462	1725	1729	Treg	T025	C0039198
28222462	1732	1749	enhancing effects	T080	C1280500
28222462	1753	1758	IGF-1	T116,T123	C0021665
28222462	1765	1770	IGF-1	T116,T123	C0021665
28222462	1792	1802	modulating	T082	C0443264
28222462	1803	1812	Treg cell	T025	C0039198
28222462	1822	1828	action	T052	C3266814
28222462	1832	1834	GO	T047	C0339143